Authors
Latest:
A New Game Plan for Pharma HRNew dynamics are forcing the industry's human resource departments to rethink their operational game plans. The drivers-consolidation, globalization, scientific advances, public policy, and competition-have pushed HR leaders into new territory to address business needs.
Latest:
Where Caremark Meets Park: A New Era of Regulatory Compliance and Criminal LiabilityThe Caremark and Park doctrines require directors and managers of life sciences companies to address regulatory compliance proactively and vigorously.
Latest:
Earning the Public Trust—and Keeping ItThe industry needs credibility with consumers to make a spoonful of risk go down. So how does pharma speak to top concerns?
Latest:
Part 3: How to Enforce Post-Employment RestrictionsCourts are often hesitant to enforce such restrictions, so employers should take certain steps prior to and in the process of filing such a lawsuit.
Latest:
How Not to Handle RebatesIn these cost cutting times, no drugmaker can afford to keep shoveling money down the Rebate Black Hole. Here's how to optimize your ROI and push back against the growing pressure of third-party rebates
Latest:
Magic MoleculesPharm Exec's Pipeline Report is packed with 25 of the year's most eye-catching experimental drugs. What's their secret? No smoke or mirrors-just innovative science, therapeutic value, and good business sense.
Latest:
Site Activation: The Key to More Efficient Clinical TrialsA new study of hundreds of thousands of clinical trial records reveals that the overall length of a trial is directly related to how long it takes to activate the study sites - and that most companies are wasting precious weeks and even months in activation. Here's how to improve your performance.
Latest:
Wyeth V. Levine: An Attorneys' PerspectiveLawyers from Duane Morris LLP offer their take on the Supreme Court's groundshaking preemption decision
Latest:
Crisis Preparedness in an Always-On Digital WorldThe first 120 minutes of a crisis can determine the public’s perception of an organization. And in today’s digital world, companies are more at risk than ever to viral attacks from unexpected sources.
Latest:
The Rise and Fall of Pharma ReputationsAs a reputation driver, ethical behavior has increased steadily in importance over the last three years.
Latest:
Lifecycle: End GameVery few drugs live forever. Barring remarkable scientific advances and radical market dynamics, most drugs hit old age-and sharply declining sales-several years before their patent expires. But some drugs go out with a bang, not a whimper.
Latest:
The Intelligence DiariesBusiness intelligence in a time of greater transparency is a whole new ball game. To play it well, be sure to look for surprising insights, expand your list of competitors of interest, and don't let Google be your only guide.
Latest:
The Lesser of Two EvilsIs the American Medical Association's (AMA) Prescribing Data Restriction Program (PDRP) the answer to physicians' privacy concerns, or will it just hamper the relationship between rep and doc? Observant LLC recently gauged reactions to the PDRP and doctors' expectancies of how this initiative affects physicians' practices and their relationships with pharmaceutical representatives. The findings suggest that the initiative may have paradoxical negative implications for physicians.
Latest:
Bottom Line BoosterGiven the colossal revenue generated by just one blockbuster drug, it's no surprise that R&D always finds its way to the top of management's agenda. But now more than ever, pharmaceutical companies can't thrive on discovery alone. Price pressure from the public and private sectors drives companies to create savings through operational efficiencies. One of the biggest areas for financial gain"better management of capital assets"is often overlooked.
Latest:
Salesforce Survey 2008Welcome to the new employer's market for reps. The Hay Group's annual survey reports how, as the primary sales force contracts, so too does its pay.
Latest:
FDA vs. the IndividualWho should make decisions about drug safety-FDA or patients and doctors? In this excerpt from his important new book Overdose, the renowned (and ever controversial) legal scholar Richard A. Epstein argues that the current system overvalues risk, ignores individual differences, and needlessly deprives patients of valuable treatments.
Latest:
Legal: E-headacheDocuments from R&D, clinical affairs, regulatory, and sales and marketing can be in the millions. Throw electronic information into the mix, and the number of documents required for litigation increases exponentially.
Latest:
Drug Safety: Failure to CommunicateMany see Vioxx and Avandia as clear signs that the drug safety system has failed. As soon as reports of these drugs' adverse events began to flood the media, consumers-and Congress-demanded to know: "Why didn't we know sooner?"
Latest:
Vouchers: More Data, Fewer DollarsSampling is a sales rep's foot in the door to doctors' offices and the quickest way to get products into consumers' hands. That's why reps handed out $5 billion worth of the freebies last year, spending 30 percent of companies' promotional budgets in the process. Despite that huge investment, few product managers can assess its impact on product inventory, consumer demand, prescription rates, or market share. But sampling's greatest failure is its inability to provide the healthcare industry with product-use or patient data.
Latest:
Sharing IP, Sharing RiskThanks to growth in international trade, rapid technological innovation, and a willingness to share intellectual property (IP), the number of corporate cross border alliances has grown steadily.
Latest:
Hits Like a BRICThe first wealth is health, wrote American thinker Ralph Waldo Emerson. Indeed, history has taught us (even before Emerson) that health and wealth are inextricably linked-the more money one has, the healthier one is likely to be.
Latest:
Glaxo Vies for a Second Act in HIVA novel joint venture between Glaxo and Pfizer is big on promise. But the combined portfolio and pipeline of HIV drugs? Not so much.
Latest:
The Lesser of Two EvilsIs the American Medical Association's (AMA) Prescribing Data Restriction Program (PDRP) the answer to physicians' privacy concerns, or will it just hamper the relationship between rep and doc? Observant LLC recently gauged reactions to the PDRP and doctors' expectancies of how this initiative affects physicians' practices and their relationships with pharmaceutical representatives. The findings suggest that the initiative may have paradoxical negative implications for physicians.
